The Thesis
PanicFade v4 bets on a well-documented behavioural edge: markets overreact to negative headlines, and oversold quality names tend to revert toward fundamentals. The rules are disciplined rather than clever — buy when sentiment drops below -0.4 and the name is already technically oversold (RSI14 under 35, trading below its SMA20), then size into the panic. Exits are symmetric: take reversion when RSI14 clears 50 or price reclaims the SMA20, and hard-stop on fresh lows under continued negativity, treating that as a genuine fundamental break rather than noise.
The approach is grounded in recent sentiment-feedback literature (arXiv:2509.11970, 2025, and corroborating work in JRFM/MDPI) on asymmetric overreaction and reversion. Requiring both a sentiment shock and a price-defined oversold condition is a sensible guard — it avoids catching falling knives on sentiment alone.
Backtest and Validation
The headline numbers are respectable and, importantly, honest about their limits. Over 1,233 trading days the strategy returned 37.93% (final equity $13,793 on $10k), a 6.79% CAGR, with a 0.96 Sharpe, 9.3% max drawdown, and a 62.88% win rate across 530 trades.
What lends credibility is the walk-forward validation. All 4 of 4 folds were positive, and performance improved across time rather than front-loading: fold returns climbed from 1.6% and 3.88% in the choppy 2021–2024 windows to 10.14% and 21.7% in the most recent fold, where Sharpe reached 2.44 on just a 2.6% drawdown. Out-of-sample stats are strong — a 0.985 PSR and a 0.56 DSR across 27 trials, meaning the edge survives a haircut for multiple-testing bias. That DSR is the number I trust most here: it says the strategy is probably real, not merely the best of many tries.
The Risks
A few caveats deserve equal billing. The 6.79% CAGR is modest — this is a low-drawdown, steady-grind profile, not a return machine, and its 0.96 in-sample Sharpe is far below the flattering 2.44 of the final fold. Turnover is extreme at 5,807%, so real-world slippage and spreads could erode the edge more than the flat $530 modelled fees suggest. And the standout recent fold coincides with a benign, trending tape; mean-reversion strategies historically suffer when a genuine regime break turns "panic" into a justified repricing — precisely the scenario the hard-stop is meant to catch, but stops are imperfect.
Recent Activity
Worth noting: the live book has been completely dormant. Every scheduled run from 18 through 25 August executed zero trades and rejected zero — cash and total equity have sat flat at $10,000 all week. That is not a failure; it is the strategy working as designed. No name in its 24-stock large-cap universe has simultaneously tripped the sentiment and oversold thresholds. A contrarian panic-fader should do nothing when there is no panic to fade.
Verdict
PanicFade v4 is a well-validated, conservative strategy with a defensible thesis and unusually clean out-of-sample evidence. The patience it is currently showing is a feature. The open questions are whether its edge holds under live transaction costs and whether its stops are fast enough when overreaction turns out to be foresight.